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The world is on the brink of failing a critical test: the one measuring 
whether the international community is willing or able to end a global 
pandemic without leaving anyone behind. Wealthy countries have 
bought up vast vaccine supplies, leaving poorer ones to cope with 
extreme scarcity. An international initiative known as the COVID-19 
Vaccine Global Access Facility (COVAX) aims to distribute vaccines 
widely and equitably, but it is short of funds. At best, COVAX will 
reach only a small portion of the populations of low-income countries 
this year. The South African government has aptly warned of a 
coming global “vaccine apartheid.”   
There is still time to manage this differently. Wealthy countries have a 
moral duty to help distribute vaccines. It is also in their economic 
interest. Instead of hoarding supplies, these countries should 
reallocate doses to low- and middle-income countries and provide 
funding to ensure that the most vulnerable populations—including 
minorities and stateless people—and, ultimately, entire populations 
are immunized, regardless of income.  
A SMART SACRIFICE  
Political leaders face strong pressures to prioritize vaccinating their 
own populations. The impulse to care first for one’s own people can 
be morally justified but only within limits. All people have equal 
worth, with similar aspirations for health and productivity. The 
equitable distribution of vaccines—as well as tests and therapies—is 
an ethical and humanitarian imperative. It is also the most efficient 
way to address or reverse the crises that the coronavirus pandemic 
has set in motion, many of which will soon enough affect all nations, 
whether they have vaccine supplies or not.   
While the pandemic persists, progress in other areas of global health, 
such as immunizing children and eradicating polio, sharply reverses. 
Because of COVID-19, some 1.5 million more people were projected to 
die from AIDS, tuberculosis, and malaria in 2020. That number 
approaches that of the world’s COVID-19 deaths in the same period. 
The number of people experiencing or at risk of acute hunger has 
roughly doubled in the last year, and the World Bank estimates that 
the pandemic has thrust 100 millionpeople into extreme poverty, a 
fate another 50 million are expected to suffer by the end of this year. 
Women and girls confront a greater risk of gender-based violence, 
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including rape, child marriage, and sex slavery, during the pandemic. 
And school closings and inaccessible remote learning have left 463 
million children without formal education.   
Only by vaccinating the world’s population can these destabilizing 
and immiserating trends be reversed or brought to heel. Large 
clusters of disease in low-income countries risk reseeding the 
pandemic in high-income countries—and such unchecked spread will 
hinder the global economic recovery and undermine the security of 
governments worldwide.   
To distribute enough vaccines, drugs, and tests to developing 
countries will cost an estimated $24 billion in 2021. That is a 
significant sum at a time when even high-income economies have 
been battered. But the investment will bring benefits that far outstrip 
the cost. The International Monetary Fund has projected that 
worldwide vaccination would add nearly $9 trillion to the global 
economy by 2025—conversely, the RAND Corporation has 
projected that for each year that low-income countries cannot 
access vaccines, the combined GDP of high-income 
countries would fall by $100 billion. The leaders of 
wealthy democracies must look beyond today, or their 
decisions will haunt them tomorrow.    
REALLOCATING RIGHT  
True justice would require all high-income countries to relinquish 
their separately purchased vaccines and instead participate in 
COVAX. Doing so would ensure that vaccines were allocated on an 
equitable basis and that the most vulnerable everywhere were 
protected first, regardless of the ability to pay. But such a solution is 
politically implausible, given that wealthy countries have already 
begun to distribute the doses that they have purchased for 
themselves.   
Remarkably, even some COVAX participants have become part of the 
problem.  Australia, Canada, and the European Union, for instance, 
have entered separate purchase agreements with vaccine makers, 
buying scarce supplies directly from producers and starving COVAX 
of doses. These countries seek to have it both ways, and current rules 
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do not appear to impede them: they can join the global effort for 
equitable vaccine distribution and still secure early access for 
themselves. But the two efforts are in tension. The more supplies rich 
nations procure, the fewer doses remain for those who rely on 
COVAX.   
An equitable and truly effective worldwide vaccination program 
requires wealthy nations to reallocate their vaccine supplies. Canada, 
the EU, and the United States have all signaled some willingness to 
share doses that exceed their national needs. But sharing on the 
margins is insufficient. The EU, the United States, and COVAX 
should instead devise a plan that commits all countries that have 
secured doses to reallocating them. High-income countries are 
already vaccinating their vulnerable populations. But the doses that 
will be procured later this year—which are expected to be used for the 
general, low-risk populations of these high-income countries—can 
still be reallocated to COVAX.  
COVAX set an initial goal of covering the most vulnerable 20 percent 
of participating countries’ populations in 2021. This goal is far below 
the threshold needed for herd immunity and much lower than what 
high-income countries would tolerate for themselves. Reallocation 
would enable the facility to exceed that target, jump-start economies, 
and save lives. At the same time, all countries should increase their 
funding for the Access to COVID-19 Tools Accelerator (ACT-
Accelerator), a global collaboration spearheaded by the World Health 
Organization (WHO) for the equitable distribution of COVID-19 
testing and drugs. Doing so could raise the $24 billion that will be 
needed this year to secure global access not only to vaccines but also 
to testing, personal protective equipment, and therapies that can aid 
countries when vaccine access lags. These technologies would allow 
specialists to track and control the virus’s evolution and spread.   
 
A SMALL PRICE TO PAY  
Wealthy countries will have to shoulder the greater part of the global 
burden of ending the pandemic. Funding obligations should be 
proportional to population size and income, as is the case with UN 
dues. Wealthy countries have already injected approximately $13 
trillion into their own economies. But they have increased their social 
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protection assistance—programs meeting people’s basic needs, such 
as for food and unemployment support—to low- and middle-income 
countries only by less than $6 billion as of last October. Wealthy 
countries should commit at least two percent of their COVID-19 
spending to response and recovery measures in low- and middle-
income countries. Doing so meets not only a moral obligation but also 
a legal one, under international human rights law. According to 
the International Covenant on Economic, Social, and Cultural Rights, 
wealthy countries have an obligation to “take steps, individually and 
through international assistance and co-operation” to realize every 
person’s human rights. Moreover, helping other countries fight the 
pandemic can boost global markets and stabilize governments, 
strengthening the economic recovery and national security interests 
of wealthy countries, as well.   
President-elect Joe Biden has promised a major COVID-19 recovery 
package early in his administration. If the United States and other 
wealthy nations were to commit two percent of such spending abroad, 
they would release some $260 billion in funds. That amount could 
cover the needs of the ACT-Accelerator and more. The sum would 
also allow the UN World Food Program to meet the needs of more 
than 270 million people facing or at direct risk of acute food 
insecurity. It would further help the UN meet the needs of the 235 
million people requiring humanitarian aid, such as emergency 
medical assistance or rescue from natural disasters or political 
persecution—a figure that has dramatically increased because of the 
pandemic. The funds could help strengthen social safety nets in low-
income countries and bolster grassroots organizations with access to 
marginalized populations.   
 The world’s major economies should not only commit some of their 
pandemic relief spending to countries with low incomes but also 
extend a debt service moratorium through 2022 and cancel many of 
the poorest countries’ debts. They should support the International 
Monetary Fund in creating Special Drawing Rights, an asset added to 
countries’ foreign reserves that can be converted into currency. The 
sooner the world jump-starts the economies of low- and middle-
income countries, the sooner those countries will be able to finance 
their own vaccines, drugs, and diagnostic tests when the next 




Countries should aim to equitably distribute resources not only 
around the world but also within their borders. They must steward 
their vaccine supplies transparently and equitably, including to 
undocumented immigrants, refugees, and other marginalized 
communities hard hit by the pandemic, such as people of color in the 
United States, migrant workers in Singapore, and indigenous peoples 
in Brazil. Doing so will require policymakers to set ethical priorities 
but also to undertake community outreach efforts that aim at 
ensuring inclusion.   
Even as the wealthy countries undertake the hard work of looking 
inward, they must not neglect the most vulnerable global populations, 
some of whom reside within their borders. These include refugees, 
internally displaced persons, asylum seekers, and stateless people. 
Such communities are often crowded together, which puts them at 
particular risk of infection, and their lack of citizenship in their 
countries of residence makes them especially likely to be left out of 
health care and vaccination campaigns. Ensuring the immunization 
of such communities is a matter not only of fairness but also of 
prevention of further spread. All countries should prioritize these 
populations, and COVAX should require recipient countries to cover 
them. In fact, the facility should increase its 2021 vaccination goal to 
include the 80 million forcibly displaced people and at least 10 
million stateless people.   
The world will almost certainly face another pandemic. The next 
novel outbreak may or may not compare to COVID-19 in magnitude 
and severity; but to anticipate its eventuality, the WHO, with full 
support from the world’s governments, should set up a standing fund 
to cover vaccine research, development, and allocation. The G-7 or G-
20, for example, could spearhead this fund. All countries should 
further agree upon binding rules for the equitable distribution of 
vaccines, therapeutics, and testing by, for instance, adopting 
a separate global health treaty that includes these rules or reforming 
the International Health Regulations, which address the obligations 
of countries and of the WHO to public health emergencies.    
The equity action agenda we have proposed will not only save lives 
and propel economic recovery but also demonstrate that today’s 
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fractured world can come together for a common purpose. Such 
cooperation will ultimately serve a host of global priorities—from 
climate change to future global health security—that require shared 
endeavor and a commitment to justice. 
	
